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Randomised phase IIAbstract Background: Oxaliplatin-capecitabine (OxCap) and carboplatin-paclitaxel (Car-
Pac) based neo-adjuvant chemoradiotherapy (nCRT) have shown promising activity in loca-
lised, resectable oesophageal cancer.
Patients and methods: A non-blinded, randomised (1:1 via a centralised computer system),
‘pick a winner’ phase II trial. Patients with resectable oesophageal adenocarcinoma  cT3
and/or  cN1 were randomised to OxCapRT (oxaliplatin 85 mg/m2 day 1, 15, 29; capecitabine
625 mg/m2 bd on days of radiotherapy) or CarPacRT (carboplatin AUC2; paclitaxel 50 mg/
m2 day 1, 8, 15, 22, 29). Radiotherapy dose was 45 Gy/25 fractions/5 weeks. Both arms
received induction OxCap chemotherapy (2  3 week cycles of oxaliplatin 130 mg/m2 day
1, capecitabine 625 mg/m2 bd days 1e21). Surgery was performed 6e8 weeks after nCRT. Pri-
mary end-point was pathological complete response (pCR). Secondary end-points included
toxicity, surgical morbidity/mortality, resection rate and overall survival.
Statistics: Based on pCR  15% not warranting future investigation, but pCR  35% would,
76 patients (38/arm) gave 90% power (one-sided alpha 10%), implying that arm(s) having 10
pCR out of first 38 patients could be considered for phase III trials. ClinicalTrials.gov:
NCT01843829. Funder: Cancer Research UK (C44694/A14614).
Results: Eighty five patients were randomised between October 2013 and February 2015 from
17 UK centres. Three of 85 (3.5%) died during induction chemotherapy. Seventy-seven pa-
tients (OxCapRT Z 36; CarPacRT Z 41) underwent surgery. The 30-d post-operative mor-
tality was 2/77 (2.6%). Grade III/IV toxicity was comparable between arms, although
neutropenia was higher in the CarPacRT arm (21.4% versus 2.6%, p Z 0.01). Twelve of 41
(29.3%) (10 of first 38 patients) and 4/36 (11.1%) achieved pCR in the CarPacRT and Ox-
capRT arms, respectively. Corresponding R0 resection rates were 33/41 (80.5%) and 26/36
(72.2%), respectively.
Conclusion: Both regimens were well tolerated. Only CarPacRT passed the predefined pCR
criteria for further investigation.
ª 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Treatment by surgery alone confers poor outcome in
patients with resectable oesophageal cancer. Neo-
adjuvant chemoradiotherapy (nCRT) preceding sur-
gery improves disease-specific survival. Efforts to
improve these outcomes have focussed on the addition
of adjuvant chemotherapy and/or radiotherapy to sur-
gical treatment. However, most of the randomised
studies evaluating nCRT were performed over two de-
cades ago, were heterogenous in design, often under-
powered, largely tested platinum/fluropyrimidine-based
regimens, and reported a high incidence of treatment-
related toxicity and post-operative mortality [1].
Recently, the CROSS trial, which showed that nCRT
was associated with a doubling of median overall sur-
vival (OS) to 49.4 months compared to surgery alone,
has established a new standard of care [2]. In that study,
the incidence of grade IIIeIV haematological and non-
haematological toxicity (7% and 13%, respectively) in
the nCRT arm was one of the lowest reported in the
literature and post-operative mortality (4%) was iden-
tical to the surgery-only arm.In the United Kingdom (UK), due to concerns
regarding increased post-operative morbidity, clinicians
favoured the use of neo-adjuvant or peri-operative
chemotherapy alone in patients with locally advanced,
resectable, gastro-oesophageal cancer (MAGIC [3],
OE05 [4], ST03 [5], NOGCA [6]). However, advances in
radiotherapy techniques, demonstration of enhanced
radiotherapy quality assurance through the SCOPE trial
[7], and centralisation of gastro-oesophageal surgery
encouraged the Upper GI Clinical Studies Group of the
National Cancer Research Institute and Cancer
Research UK to support and fund the first multicenter
study of pre-operative CRT in the UK.
Oxaliplatin has been shown to be comparable in ef-
ficacy to cisplatin in advanced gastro-oesophageal cancer
and can be conveniently delivered as a 2-h infusion [8].
Single arm phase IeII studies have demonstrated feasi-
bility of oxaliplatin-based nCRT [9e15]. One rando-
mised phase II study comparing oxaliplatin-5FU-based
CRT with cisplatin 5FU-based CRT in patients with
inoperable but localised oesophageal cancer has
demonstrated no significant difference in survival or
toxicity but the ease of administration of oxaliplatin over
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have chosen to investigate an oxaliplatin rather than
cisplatin-based platinum-fluoropyrimidine regimen.
NEOSCOPE was a randomised phase II trial that
evaluated the efficacy and toxicity of OxCapRT and
CarPacRT in the pre-operative treatment of patients
with locally advanced resectable oesophageal cancer and
assessed the feasibility of safely introducing nCRT into
clinical practice in the UK. We felt it was necessary to
evaluate the two regimens as there was a growing
international shift to the use of CarPacRT based on
historic comparison with the traditional platinum-
fluoropyrimidine regimens rather than through a rand-
omised trial. The aim was to ‘pick a winner’ that could
be taken forward to a future Phase III trial where neo-
adjuvant CRT would be compared with pre-operative
chemotherapy.2. Methods
In this multicenter, randomised, open-label, ‘pick a
winner’, phase II trial, we recruited patients who fulfilled
the following key eligibility criteria: resectable adeno-
carcinoma (ACA) of the oesophagus including Siewert
type 1 or 2 tumour of the gastro-oesophageal junction
(GEJ) (maximum extension beyond GEJ of 3 cm), with
cT stage  3 and/or cN stage  1, World Health
Organisation performance status 0e1, maximum disease
(T þ N) length 8 cm, adequate respiratory, cardiac,
haematological, renal and hepatic function and 18
years old. Staging investigations included contrast-
enhanced computed tomography (CT) scan of thorax
and abdomen, endoscopic ultrasound (EUS), positron-
emission tomography (PET)/CT scan, and laparoscopy
(for lower third and GEJ tumours). The study protocol
was published previously [17] and is included as
Supplementary Material.
All patients provided written informed consent to a
medical doctor and research nurse who then telephoned
the Wales Cancer Trials Unit (WCTU) to randomly
assign (1:1) the patients to OxCapRT or CarPacRT by
stratified minimisation with a random element (80:20)
via a centralised computer system. Randomisation was
stratified by recruiting hospital, cT stage (T1/T2 versus
T3/T4), and cN stage (N0 versus Nþve).
Induction chemotherapy (ICT) in both arms con-
sisted of two 3-weekly cycles of oxaliplatin (130 mg/m2
intravenously on day 1) and capecitabine (625 mg/m2
orally twice daily from day 1 to day 21). During the
CRT phase, patients randomly assigned to the
OxCapRT arm received oxaliplatin (85 mg/m2 on
intravenously on days 1, 15, 29) and capecitabine
(625 mg/m2 bd orally on days of radiotherapy). Patients
assigned to the CarPacRT arm received carboplatin
AUC2 and paclitaxel 50 mg/m2 with both drugs
administered intravenously on days 1, 8, 15, 22, 29 ofradiotherapy. Capecitabine tablets could be dissolved
for patients with swallowing difficulties.
The radiotherapy was planned using intravenous
contrast CT simulation with minimum 3-mm CT slices.
45 Gy in 25 daily fractions, prescribed according to
recommendations of the International Commission on
Radiation Units and Measurements (ICRU-50), was
delivered Monday to Friday as a 3D, conformally
planned single-phase treatment, usually with four
radiotherapy fields. Gross tumour volume (GTV) was
defined using diagnostic CT scan, endoscopy, EUS and
PET scan (when available). The clinical target volume
(CTV) was calculated by growing the GTV by 2 cm
manually along the oesophagus superiorlyeinferiorly
and 1 cm radially, editing out lungs and bronchus, heart,
liver, aorta and vertebrae. The planning target
volume was created by growing CTV 1 cm superi-
orlyeinferiorly and 0$5 cm radially. 4D CT simulation
was encouraged for lower oesophagus/GEJ tumours
(included as Supplementary Material: NEOSCOPE
Radiotherapy Treatment Planning and Delivery docu-
ment). Cone-Beam CT verification was used on the first
3 fractions of radiotherapy treatment and weekly
thereafter. The Radiotherapy Trials Quality Assurance
(RTQA) process has been previously described and
included a pre-accrual component, and on-trial real-
time or timely retrospective review [17,18].
Toxicity was assessed as per US National Cancer
Institute’s Common Terminology Criteria for Adverse
Events (CTCAE version 4.03). Capecitabine compliance
was assessed by tablet count at each visit. Restaging CT/
PET-CT was undertaken 4e6 weeks after CRT and
surgery was performed at 6e8 weeks after completion of
CRT. Type of surgery was not mandated. The resection
specimens were evaluated by the local pathologists as
per detailed trial-specific guidelines (see appendix 4 of
the trial protocol). Post-surgical assessments for
toxicity, post-operative morbidity and review of disease
status were performed at 30 d, 6 months and 12 months
following surgery. Investigations and follow up beyond
12 months were done as per institutional standard. The
choice of treatment at relapse was left to the discretion
of the treating clinician.
The primary end-point was pathological complete
response (pCR) as reported by the local pathologists
according to the trial-specific guidelines referred to
above. pCR was defined as complete absence of tumour
in the whole resected specimen (ypT0N0). Cases with
residual primary tumour were graded using the Mandard
tumour regression grading system [19]. Secondary end-
points were feasibility of recruitment, toxicity (CTCAE
version 4.03), peri-operative morbidity/mortality,
circumferential resection margin positivity rate, and
overall survival. A resection margin was defined as
being positive when tumour cells were present directly at
the resection margin or within 1 mm of the resection
margin.
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between arms. The sample size calculations were based
on the maximum of two binomial random variables and
followed the methodology described by Dunnett [20]
with input from the MRC North West Hub for Trials
Methodology Research (see Appendix A). A pCR of
15% was not considered large enough to warrant further
investigation, whilst a pCR of 35% was considered
worthwhile. The null hypothesis was that pCR1 Z
pCR2 Z 0.15 where pCR1 and pCR2 are the response
rates for the two treatments. A sample size of 76 (38
patients/arm) gave a one-sided type I error of 10% and a
power of 90% of achieving significance if patients on one
treatment had a response rate of 35% whilst those on the
other had response rate of 15%. A priori rules were
specified to decide whether or not one or both trial
arm(s) warranted future investigation in phase III trials
(Supplementary Table 1) [17]. The study sought to re-
cruit 85 patients to allow for a potential 10% drop-out
rate before resection.
Data were analysed according to a pre-specified anal-
ysis plan using the Stata SE 14 statistical package at the
time the primary end-point had been collected in all pa-
tients (further follow up is ongoing). All analyses were bys
Fig. 1. CONSORT flow diagram of trial participants. *Three of the pat
toxicities during induction chemotherapy.intention to treat except the toxicity analyses which were
conducted only in those patients who had some treatment
during the related treatment phase and the surgical
complications analysis only in those who had surgery.
Proportions were compared using chi-square tests.
ClopperePearson exact binomial method was used to
calculate confidence intervals for the primary end-point.
The trial protocol was approved by the UK Medi-
cines and Healthcare products Regulatory Agency and a
Multi-Centre Research Ethics Committee, sponsored by
Velindre NHS Trust and coordinated by the WCTU at
Cardiff University.3. Results
Eighty-five patients were randomised from 17 UK centres
between 10 October 2013 and 12 February 2015 (Fig. 1).
At the time of analysis, all patients had completed 30-
d post-operative assessment or died or withdrawn from
the study. Patient and tumour baseline characteristics
were balanced between the groups (Table 1).
Toxicities during induction chemotherapy and nCRT
are shown in Table 2. There were 3 deaths (all seriousients allocated to OxCapRT were actually given CarPacRT due to
Table 1
Baseline characteristics.
OxCapRT (n Z 42) CarPacRT (n Z 43)
n % n %
Sex Male 36 85.7 33 76.7
Female 6 14.3 10 23.3
Age Median (IQR, range) 65 (58e72, 46e77) 64 (61e68, 29e76)
cT stage T2 6 14.3 3 7.0
T3 36 85.7 37 86.0
T4a 0 0.0 3 7.0
cN stage N0 12 28.6 16 37.2
N1 21 50.0 20 46.5
N2 8 19.0 6 14.0
N3 1 2.4 1 2.3
Site of predominant tumour Middle third (24  32 cm) 6 14.3 2 4.7
Lower third (32e40 cm) 32 76.2 39 90.7
Missing 4 9.5 2 4.7
Time from staging scan to randomisation (d) Median (IQR, range) 27 (19e39, 8e56) 28 (23e34, 2e51)
Maximum total disease length from EUS, PET and CT Median (IQR, range) 5.85 (4.7e6,2e8) 5.7 (5e7, 2e8.3)
WHO performance status 0 37 88.1 35 81.4
1 5 11.9 8 18.6
Time from randomisation to start of treatment (d) Median (IQR, range) 4 (2e6, 0e18) 4 (3e6, 0e14)
Table 2
Grade III/IV CTCAE toxicities during treatment.
System organ class Adverse event Induction chemotherapy CRT
Both arms (n Z 85) OxCapRT (n Z 38) CarPacRT (n Z 42)
n % n % n %
Any toxicity 27 31.8 16 42.1 22 52.4
Any haematological toxicity 2 2.4 6 15.8 12 28.6
Blood and lymphatic
system disorders
Anaemia 1 1.2 1 2.6 0 0.0
Febrile neutropenia 0 0 0 0.0 1 2.4
Cardiac Chest pain 2 4.8 0 0.0 0 0.0
Gastrointestinal Any in this class 15 17.6 5 13.2 8 19.0
Abdominal pain 2 2.4 1 2.6 0 0.0
Colonic spasm 0 0.0 1 2.6 0 0.0
Constipation 0 0.0 1 2.6 0 0.0
Diarrhoea 7 8.2 0 0.0 1 2.4
Dry mouth 1 1.2 1 2.6 0 0.0
Dysphagia 6 7.1 2 5.3 2 4.8
GI haemorrhage 0 0.0 0 0.0 1 2.4
Mucositis 1 1.2 0 0.0 0 0.0
Nausea/vomiting 6 7.1 0 0.0 0 0.0
Oesophageal pain 0 0.0 0 0.0 1 2.4
Oesophagitis 1 1.2 2 5.3 2 4.8
General disorders Fatigue 9 10.6 4 10.5 6 14.3
Injury Fall 0 0.0 1 2.6 0 0.0
Investigations Lymphocyte decrease 0 0.0 3 7.9 3 7.1
Platelet decrease 1 1.2 1 2.6 0 0.0
Neutrophil decrease 0 0.0 1 2.6 9 21.4
White blood cell decrease 0 0.0 2 5.3 2 4.8
Metabolism Anorexia 2 2.4 2 5.3 0 0.0
Other 4 4.7 0 0.0 0 0.0
Nervous system Peripheral neuropathy 5 5.9 0 0.0 0 0.0
Pharyngolaryngeal dysaesthesia 1 1.2 0 0.0 0 0.0
Respiratory Dyspnoea 1 1.2 0 0.0 1 2.4
Vascular Hypertension 1 1.2 1 2.6 0 0.0
Hypotension 0 0.0 0 0.0 1 2.4
Peripheral ischaemia 1 1.2 0 0.0 0 0.0
Thromboembolic events 1 1.2 1 2.6 1 2.4
CTCAE, Common Terminology Criteria for Adverse Events.
S. Mukherjee et al. / European Journal of Cancer 74 (2017) 38e4642
S. Mukherjee et al. / European Journal of Cancer 74 (2017) 38e46 43adverse reactions) during induction OxCap chemotherapy
(3/85, 3.5%): two (1 multiple organ failure following
chemotherapy induced diarrhoea and one secondary to
diarrhoea/acute ischaemic leg) in patients randomised to
the OxCapRT arm, and one (superior mesenteric artery
thrombus and small bowel ischaemia) in patients
randomised to the CarPacRT arm. There was no
difference in the rate of any grade IIIeIV toxicities
between the arms during induction chemotherapy. During
CRT, the rate of any grade IIIeIV toxicity (52.4% [22/42]
versus 42.1% [16/38], c2Z 0.8447, pZ 0.358) and rate of
haematological grade IIIeIV toxicity (28.6% [12/42]
versus 15.8% [6/38], c2Z 1.8692, pZ 0.172) were higher
in the CarPacRT arm, although neither reached statistical
significance. There was significantly higher incidence of
grade IIIeIV neutropenia in the CarPacRT arm (21.4%Fig. 2. Percent of total chemotherapy dose during CRT (nZ 85).
Table 3
Surgery.
Patients randomised
Patients not having surgery, n (%)
Disease progression
Comorbidity
Died before surgery
Patients having surgery
Days between finishing pre-surgical treatment and surgery, median (n, IQR
Number of days in hospital post-surgery as an in-patient (d), median (n, I
30-d post-operative mortality
30-d post-operative complicationsc Any complication
Respiratory complications
Cardiac complications
Wound infection
Chylothorax requiring treatment
Haemorrhage requiring transfusion o
Other complications
Anastomotic leak None
Radiological/endoscopic
Missing data
a Multiple organ failure following cardiac arrest. Hospital acquired pneu
b Anastomotic leak.
c Uses a denominator of 35 in the OXCAP-CRT armdone patient has[9/42] versus 2.6% [1/38], post hoc c2 Z 6.4447,
p Z 0.011), though febrile neutropenia was uncommon.
During induction chemotherapy, the median per-
centage of protocol dose of oxaliplatin:capecitabine was
100 interquartile range (IQR: 98e101):97 (IQR: 92e104)
and 100 (IQR: 96e100):100 (IQR: 93e104) in the
OxCapRT and CarPacRT arms, respectively. During
CRT (Fig. 2), the median percentage of protocol dose of
oxaliplatin:capecitabine was 99 (IQR: 59e100):98 (IQR:
72e106) and the median percentage of protocol dose of
carboplatin:paclitaxel was 85 (IQR:70e100):83 (IQR:
73e101). One patient in each arm did not receive cycle
two of induction chemotherapy due to toxicities (1 chest
pain, 1 multiple toxicities). There was only one treatment
delay during induction chemotherapy due to a haema-
tological toxicity in the OxCapRT arm. Four patients (2
deaths, 2 toxicities) in the OxCapRT and one (death) in
the CarPacRT arm did not start CRT. Additionally,
three patients initially randomised to the OxCapRT arm
were withdrawn from trial treatment due to toxicities
during induction chemotherapy (they were actually given
CarPacRT instead but were not counted in that arm for
this analysis). These imbalances are the reason for the
higher proportion of patients receiving no chemotherapy
drugs in the OxCapRT arm during CRT.
All centres passed pre-trial quality assurance (QA)
prior to entering patients into the trial. Eighty-three
radiotherapy (RT) contours and plans were reviewed
(this included three patients who ultimately did not
undergo CRT), 39 (47%) underwent prospective review
prior to start of RT and 44 (53%) underwent timely
retrospective review wherein feedback was provided by
the 3rd fraction of RT. Eight cases required re-OxCapRT CarPacRT
n % n %
42 43
6 14.3 2 4.7
3 7.1 1 2.3
1 2.4 0 0.0
2 4.8 1 2.3
36 85.7 41 95.3
, range) 52 (36, 47e64,37e92) 56 (41, 49e73,41e147)
QR, range) 11.5 (36, 9.5e16, 0e74) 12 (40, 10e19,0e67)
1a 2.8 1b 2.4
19 54.3 21 51.2
14 40.0 15 36.6
9 25.7 4 9.8
3 8.6 5 12.2
1 2.9 2 4.9
r intervention 2 5.7 0 0.0
9 25.7 9 22.0
32 88.9 35 85.4
0 0.0 3 7.3
4 11.1 3 7.3
monia following surgery. Adenocarcinoma of oesophagus.
missing complications data.
Table 4
Local pathologist findings.
OxCapRT (n Z 36) CarPacRT (n Z 41)
n % n %
Mandard tumour
regression grading
No residual tumour 4 11.1 12 29.3
Very few residual cancer cells 13 36.1 16 39.0
Predominant fibrosis with few tumour cells 13 36.1 10 24.4
Dominant tumour mass with fibrosis and/or vasculopathy 4 11.1 3 7.3
No histological response 0 0.0 0 0.0
Not gradeable 1a 2.8 0 0.0
Missing 1 2.8 0 0.0
Circumferential resection
margin (CRM) status
Tumour at CRM 2 5.6 3 7.3
Tumour within 1 mm of CRM 8 22.2 5 12.2
No tumour within 1 mm 26 72.2 33 80.5
ypT 0 5 13.9 12 29.3
1a 4 11.1 2 4.9
1b 8 22.2 7 17.1
2 2 5.6 4 9.8
3 17 47.2 16 39.0
ypN 0 23 63.9 31 75.6
1 6 16.7 9 22.0
2 6 16.7 0 0.0
3 1 2.8 1 2.4
Resection margin 0 (No residual disease) 26 72.2 33 80.5
1 (Microscopic residual disease) 10 27.8 8 19.5
a ypT0, ypN1.
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six of whom were either the first or second patient
recruited from the participating centre.
Compliance to radiotherapy was similar across arms
with 38 (90.5%) and 40 (93.0%) patients receiving the full
protocol dose in the OxCapRT and CarPacRT arms,
respectively (c2Z 0.1824, pZ 0.669). Two patients in the
CarPacRT did not complete radiotherapy, one due to
patient choice (43.2 Gy/24#) and one due to gastroin-
testinal haemorrhage (30.6 Gy/17#). Time from start of
randomisation to start of CRT: median of 47 d (IQR:
45e52) in the OxCapRT arm and 47 d (IQR: 45e49) in
the CarPacRT arm.
Thirty-six (85.7%) and 41 (95.3%) patients had sur-
gery in the OxCapRT and CarPacRT arms, respectively
(Fig. 1, Table 3). There was one death within 30 d post-
surgery in each trial arm and 30-d post-operative
complication rates were very similar: 19 (54.3%) and 21
(51.2%) patients in the OxCapRT and CarPacRT arms,
respectively (c2 Z 0.0712, p Z 0.790).
The results of the local pathological resection spec-
imen assessment are shown in Table 4. Four of 42 pa-
tients (8.5%, 80% confidence intervals [CIs]: 4.0e18.0; 4/
36 [11.1%] of those who had surgery) in the OxCapRT
arm had pCR, thus the phase II target of 10 out of 38
patients was not reached. In the CarPacRT arm, 10 out
of the first 38 and 12 of 43 (27.9%, 80% CIs: 19.0e38.5;
12/41 [29.3%] of those who had surgery) had a pCR,
thus passing the phase II target. The rate of R0 re-
sections also favoured the CarPacRT arm (33/41 [80.5%]
versus 26/36 [72.2%]) although the study was not pow-
ered for direct comparisons.The survival data are still immature and will be pre-
sented after longer term follow up.
4. Discussion
This phase II trial demonstrated activity warranting
further study using the CarPacRT regimen only. Both
CRT regimens were well tolerated and post-operative
morbidity was comparable between arms (around 50%).
However, neutropenia during CRT was significantly
higher in the carboplatin-paclitaxel arm (21.4% versus
2.6%, p Z 0.01), although this did not translate into
increased risk of mortality. Post-operative mortality was
low in both arms (around 2.5%). This study also
demonstrated, through the use of a detailed protocol
and robust quality assurance programme, the safety and
feasibility of introducing nCRT into clinical practice in
the United Kingdom.
The rationale for ICT before CRT was to deliver
additional systemic therapy in a disease where systemic
relapse is common, and where only half the patients
manage chemotherapy following surgical or radio-
therapy treatment [3,5,21]. However, since the inception
of the NEOSCOPE trial, two randomised phase II trials
testing the role of ICT have failed to demonstrate an
increase in OS in the ICT arm [22,23]. In the study by
Yoon et al., ICT also led to increased incidence of grade
IIIeIV thrombocytopaenia and reduction of dose in-
tensity, similar to the increase in haematological toxicity
seen in the CarPacRT arm of NEOSCOPE. Conversely,
the rates of pCR were similar in this study compared
with the CROSS trial where ICT was not used [2].
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multi-centre study to routinely utilise image-guided
radiotherapy with detailed 4D CT planning instructions
and cone-beam verification supported by high quality
peer reviewed real-time RTQA in the context of neo-
adjuvant chemoradiation for oesophageal ACA [24].
This study supports the feasibility of implementing
complex image-guided RT and will be taken forward in
the context of future oesophageal cancer radiotherapy
studies (e.g. SCOPE-2).
Given the doseresponse effect of radiotherapy in
nCRT [25], we used 45 Gy instead of the 41.4 Gy which
was used in the CROSS trial. The low mortality and
morbidity rate in this trial is reassuringdfuture trials
(accompanied by high quality RTQA programmes) may
consider 45 Gy to be a safe dose to deliver and may even
consider further dose escalation or use of hypofractio-
nated radiotherapy.
We undertook this trial in patients with ACA only as
this is the predominant (or increasingly prevalent) can-
cer subtype in Western populations. ACA may have a
different biology as well as different chemo- and radio-
sensitivity compared to squamous cell cancer (SCC),
and CROSS trial had shown different pCR rates be-
tween ACA and SCC. We believe that future trials of
nCRT should be performed separately for ACA and
SCC.
Other than true lack of efficacy or due to small
numbers, we are unable to explain the reason for the low
pCR rate in the OxCapRT arm. Previous phase I/II
studies have quoted a pCR rate of 27.3e38% in resected
patients [4], [5], [24] and the translational aspect of
NEOSCOPE will aim to characterise genetic/molecular
markers that defined the OxCapRT-responsive group.
This study has its limitations. Although this study was
randomised, a higher proportion of patients allocated to
the OxCapRT arm did not undergo surgery (6 versus 1);
additionally, three patients originally allocated to the
OxCapRT arm crossed over to the CarPacRT arm due to
toxicity during ICT (analysed as intention-to-treat).
Whereas such instances are inevitable in clinical trials,
the shift of patients may have had an impact on the pCR
rate in the trial arms, given the small number of patients
in the trial. Additionally, the trial was not powered to
detect differences in pCR between arms. A further limi-
tation of this study is that the data published here relied
on local pathological assessment. However, the trial
protocol included detailed guidance on the specimen work
up and reporting and we plan to conduct central patho-
logical assessment once the sample collection is complete.
In summary, NEOSCOPE supports further investi-
gation of CarPacRT for oesophageal nCRT, but
OxCapRT failed to pass the pre-specified pCR threshold.
Neo-adjuvant OxCapRT and CarPacRT can be both
delivered with radiotherapy to a dose of 45 Gy with
acceptable toxicity and low incidence of post-operative
30-d mortality, although induction chemotherapy maynot be necessary. High quality, image-guided CRT prior
to surgery can be used safely in the UK.
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